Disclosures
Cancer
CANCER
W.P. Weber received research support from Agendia paid to the University Hospital Basel and honoraria for lectures from MSD. A. Mueller reports personal fees from Lilly, Novartis, Pfizer, Genomic Health, Astra Zeneca, Daiichi Sankyo, Roche, Pierre Fabre, Exact Sciences, Myriad Genetics, Gilead Sciences, Glaxo Smith Kline, MSD, GlaxoSmithKline, and grants from Roche and other from Vifor Stock. Christian Kurzeder reports honoraria from Tesaro, GSK, Astra Zeneca, Novartis, PharmaMar, Genomic Health, Roche, Eli Lilly S.A., Pfizer, Daichi; consulting or advisory role for Tesaro, GSK, Astra Zeneca, Novartis, PharmaMar, Genomic Health, Roche, Eli Lilly S.A., Merck MSD, Pfizer, and travel, accommodations and expenses from GSK, Astra Zeneca, and Roche. M. Gnant reports personal fees/travel support from AstraZeneca, DaiichiSankyo, EliLilly, Menarini-Stemline, MSD, Novartis, PierreFabre, Veracyte; an immediate family member is employed by Sandoz. S. Loibl reports grants from AZ, Abbvie DSI, Molecular Health, BMS/Celgene, Gilead, Novartis, Pfizer and Roche, honorarium for ad.board and presentations from AZ, Amgen, Gilead, BMS, Novartis, Pfizer, Seagen, Sanofi, Relay, Olema, Incyte, Roche, Merck KG, Lilly and GSK, non-financial medical writing support from AZ, Pfizer, Roche, Novartis, DSI, Cellcuity outside the submitted work. In addition, S. Loibl reports a patent for VM Scope with royalties paid to institute, a patent for EP14153692.0 pending, a patent for EP21152186.9 pending, and a patent for EP15702464.7 pending. F. Fitzal reports personal fees from Novartis, Astra Zeneca, Roche and MSD. D. Egle reports personal fees from AstraZeneca, Daiichi Sankyo, Gilead, MSD, Novartis, Pfizer, Sirius, and non-financial support from Roche outside the submitted work. M. Knauer reports grants from Agendia and grants from Swiss Cancer Research during the conduct of the study; other from Myriad Advisory Board outside the submitted work. All other authors report no conflicts of interest.